AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Tonix Pharmaceuticals Secures Approval for Fibromyalgia Treatment, Shares Surge
ByAinvest
Saturday, Aug 16, 2025 8:46 am ET1min read
Tonix Pharmaceuticals' stock is up 18% after securing FDA approval for its fibromyalgia treatment. The company's shares had dropped 15% earlier in the day. The approval marks a significant milestone for Tonix and could potentially boost investor confidence in the company.
Tonix Pharmaceuticals (TNXP) saw its stock price rise by 18% following the U.S. Food and Drug Administration (FDA) approval of Tonmya™, a new treatment for fibromyalgia. The approval marks a significant milestone for the company, which had seen its shares drop by 15% earlier in the day [1].Tonmya™, a sublingual formulation of cyclobenzaprine HCl, is the first new FDA-approved therapy for fibromyalgia in over 15 years. The approval comes after two pivotal Phase 3 clinical trials involving nearly 1,000 patients demonstrated significant pain reduction compared to placebo over 14 weeks [2].
The medication is designed for once-daily bedtime use, with a sublingual formulation to facilitate rapid absorption into the bloodstream. The FDA approval follows a comprehensive safety evaluation across three Phase 3 trials with over 1,400 patients, showing that Tonmya™ was generally well-tolerated with the most common adverse effects including oral hypoesthesia, oral discomfort, and somnolence [2].
The commercial availability of Tonmya™ is anticipated in the fourth quarter of 2025, targeting a U.S. market of over 10 million adults affected by fibromyalgia. This approval represents a transformative step for Tonix Pharmaceuticals, moving the company from a development-stage entity to a potential revenue-generating commercial enterprise [1].
Tonix Pharmaceuticals will host a webcast and conference call on Monday, August 18, 2025, at 8:30 AM ET to discuss the approval of Tonmya™. The live webcast of the call will be available on the Investors section of Tonix's website [2].
References:
[1] https://www.gurufocus.com/news/3065191/tonix-pharmaceuticals-announces-fda-approval-of-tonmyacyclobenzaprine-hcl-sublingual-tablets-for-the-treatment-of-fibromyalgia-tnxp-stock-news
[2] https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet